1-4 of 4
Carlos Guillermo Romo, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Preetesh Jain, MBBS,MDDM,PhD, Hagop M. Kantarjian, MD, Raja Luthra, PhD, Graciela Nogueras Gonzalez, Elias Jabbour, Koji Sasaki, MD, Carlos Guillermo Romo, MD, Keyur P. Patel, MD PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 598.
https://doi.org/10.1182/blood.V126.23.598.598
Published: 2015
Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 4019.
https://doi.org/10.1182/blood.V122.21.4019.4019
Published: 2013
Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 2727.
https://doi.org/10.1182/blood.V122.21.2727.2727
Published: 2013
Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 2728.
https://doi.org/10.1182/blood.V122.21.2728.2728
Published: 2013